GIP and obesity disorder: It highlights the importance of considering different obesity phenotypes, such as sarcopenic obesity and metabolically healthy obesity (MHO), and discusses emerging therapeutic strategies, including dietary interventions, exercise, and pharmacological treatments like glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists.